ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1930

Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission

Dana Orange1, Phaedra Agius2, Edward F. DiCarlo3, Serene Z. Mirza4, Cristina Rozo5, Tania Pannellini5, Mark P. Figgie6, William H. Robinson7, Jackie Szymonifka5, Vivian P. Bykerk5, Laura T. Donlin8 and Susan M. Goodman5, 1Rockefeller University, New York, NY, 2New York Genome Center, New York, NY, 3Laboratory Medicine, Hospital for Special Surgery, New York, NY, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Hospital for Special Surgery, New York, NY, 6Surgery, Hospital for Special Surgery, New York, NY, 7Stanford University, Palo Alto, CA, 8Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, remission, rheumatoid arthritis (RA) and synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:   Rheumatoid Arthritis (RA) patients in clinical remission may still develop structural damage that has been attributed to ongoing synovial inflammation, sometimes only detectable by ultrasound or MRI. Here, we assess the clinical features, histologic characteristics, and transcriptional profiles of synovium from RA patients in clinical remission undergoing arthroplasty.   

Methods:   We studied 144 patients with long-standing RA (median disease duration of 12.5 years) undergoing total hip or knee arthroplasty between 2013 and 2017, and met classification criteria for RA using ACR/EULAR 2010 or 1987 criteria. Baseline data collected included age, sex, comorbidities, duration of disease, and medications. Disease activity was divided into remission (DAS 28 ESR<2.6), low disease activity (≥2.6-3.2), moderate disease activity (≥3.2-5.1), and high disease activity (≥5.1) [12]. Synovium was assessed by histologic analysis and RNA-Seq.  Statistical analysis was descriptive. Continuous characteristics are summarized by mean ± standard deviation or median [interquartile range], as appropriate. Categorical variables were compared using Fisher’s exact tests.

Results:  Of 144 participants, 15% (n=22) met DAS criteria for remission, only 1 was drug free. 17%, 53%, and 15% had high, moderate, and low disease activity at baseline as measured by DAS28(TABLE 1).  Of the patients in DAS remission: (i) histologic analysis of synovium demonstrated that 45% had moderate to marked lymphocytic infiltrates, 17% had greater than 10% plasma cells, 39% had fibrin deposition, 6% had Russell bodies, 17% had binucleate plasma cells, 17% had neutrophils, and 29% had synovial multinucleated giant cells, all features characteristic of the high inflammatory RA subtype (Figure 1), (ii) RNA-Seq analysis demonstrated that 67% had moderate levels of synovial inflammatory gene expression, and (iii) clinical assessment demonstrated that 36% of all patients in remission prior to surgery,  met DAS28 criteria for flare, 6 weeks after joint replacement.  

Conclusion:   Remission is uncommon in RA patients with long-standing disease undergoing arthroplasty. Of those in remission, synovium may be characterized by ongoing inflammation, and they remain at risk for flares. The notion that RA burns out and that patients undergoing arthroplasty have inactive disease should be re-evaluated.


Disclosure: D. Orange, None; P. Agius, None; E. F. DiCarlo, None; S. Z. Mirza, None; C. Rozo, None; T. Pannellini, None; M. P. Figgie, None; W. H. Robinson, None; J. Szymonifka, None; V. P. Bykerk, None; L. T. Donlin, None; S. M. Goodman, Roche, Novartis, 4.

To cite this abstract in AMA style:

Orange D, Agius P, DiCarlo EF, Mirza SZ, Rozo C, Pannellini T, Figgie MP, Robinson WH, Szymonifka J, Bykerk VP, Donlin LT, Goodman SM. Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/histologic-and-transcriptional-evidence-of-subclinical-synovial-inflammation-in-rheumatoid-arthritis-patients-in-clinical-remission/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histologic-and-transcriptional-evidence-of-subclinical-synovial-inflammation-in-rheumatoid-arthritis-patients-in-clinical-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology